The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives?
With its reduced injection frequency, insulin icodec (Awiqli) has the potential to provide better adherence and greater treatment satisfaction in some patients.
When high-risk drinking is identified, one of the first steps is to provide a brief intervention to support positive behaviour change related to alcohol use.
Picture this: you’re filling/verifying prescriptions and you get that all too familiar pop-up that notifies you of a QT-prolongation interaction . . . how should you approach this?
